Skip to content

News
Editor’s Feature
NeuroPulse
Industry Trends
Regulatory

CDK2 degrader

Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders

June 26, 2025 by Shajini

Big Billion deal

Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.

Categories Dealstreet, News, Oncology Tags CDK2 degrader, Gilead exclusive option license, Molecular Glue Degraders

Synopulse Weekly Pulse – November 24, 2025

Search

AI
Antibody
Cardiometabolic
Cell & Gene Tx
Deals
Dealstreet
Device Approvals
Editor’s Feature
EMA Updates
FDA Updates
Global Compliance
HTA
Industry Trends
Legal, Antitrust & IP
Litigation, Law & Policy
Market Access
Market Pulse
MedTech
Monthly Insight's
Neurology
NeuroPulse
News
Oncology
Orthopaedics
Pediatrics
Pricing and Reimbursement
Regulatory
Weekly Pulse

January 2026
December 2025
November 2025
October 2025
September 2025
July 2025
June 2025
February 2025
January 2025
October 2024
September 2024

Explore Synopulse

NeuroPulse
Deals
Market Access
Industry Trends
Regulatory

About

About Synopulse
Contact Us
Announcements

© 2026 Synopulse • Built with GeneratePress